<DOC>
	<DOCNO>NCT00687492</DOCNO>
	<brief_summary>The survey try establish proportion patient lipid-lowering pharmacological treatment reach LDL-C goal accord third NCEP ATP guideline , overall country .</brief_summary>
	<brief_title>Centralized Pan-Asian Survey Under Treatment Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>2 risk factor ( accord NCEP ATP III guideline ) Receiving lipidlowering drug treatment least 3 month without dosage change minimum 6 week . Involvement plan conduct study ( applies AstraZeneca staff staff study site ) . Previous enrolment randomisation treatment present study . Participation clinical study last 90 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>NCEP ATP III guideline</keyword>
	<keyword>survey</keyword>
</DOC>